The autosomal dominant neuronal ceroid lipofuscinoses (NCL) CLN4 is caused by mutations in the 2 synaptic vesicle (SV) protein CSPα, which is a critical co-chaperone of Hsc70 protecting synapses from 3 activity-dependent degeneration. We developed the first animal models of CLN4 by expressing either 4 CLN4 mutant human CSPα (hCSPα) or Drosophila CSP (dCSP) in fly neurons. Similar to patients, CLN4 5 mutations induced excessive oligomerization of mutant hCSPα and premature lethality in a dose-6 dependent manner. Instead of being localized to SVs, most CLN4 mutant hCSPα abnormally 7 accumulated in axons and somata, and co-localized with ubiquitinated proteins and the prelysosomal 8 markers HRS and LAMP1. Ultrastructurally, abnormal multi-laminar membrane structures were 9 frequently observed in axons and somata next to degenerative abnormalities. The lethality, 10 oligomerization and prelysosomal accumulation induced by CLN4 mutations was attenuated by reducing 11 wild type (WT) dCSP levels and enhanced by increasing WT dCSP or hCSPα levels, which indicates that 12 both CLN4 alleles resemble dominant hypermorphic gain of function mutations. Furthermore, reducing 13 the gene dosage of Hsc70 also attenuated CLN4 phenotypes. Taken together, we suggest that CLN4 14 alleles resemble dominant hypermorphic gain of function mutations that drive excessive oligomerization 15 and impair membrane trafficking. 
Introduction 1
NCLs comprise a group of progressive neurodegenerative diseases with 14 known disease-associated 2 genes, termed CLN1-14 (Haltia, CLN4 mutations, lysosomal dysfunction and neurotoxicity remains unclear. Therefore, an animal model 30 may provide critical insight into molecular and cellular mechanisms underlying CLN4 disease. 31 Here, we generated to Drosophila models for CLN4 by expressing by expressing either CLN4 32 mutant hCSPα or dCSP in fly neurons human. The human model has the unique advantage of being 33 able to separate effects of CLN4-mutant hCSPα from effects in WT dCSP. We show that both fly models 34 replicate all key pathogenic biochemical properties of CLN4 including decreased monomeric CSP levels 35 and increased levels of high-molecular weight and ubiquitinated CSP oligomers. Further analysis 1 revealed novel insights into mechanisms underlying CLN4 pathology. 2 
3

Results 4
Generation of a Drosophila CLN4 model 5 We generated a Drosophila model of CLN4 by expressing the disease-causing human proteins hCSPα-6 L115R, hCSPα-L116Δ ( Fig. 1A ; denoted as L115 and L116 from now on) and the corresponding WT 7 hCSPα control from a common genomic phi31-attP insertion site under the transcriptional control of the 8 yeast Gal4-UAS expression system (Brand and Perrimon, 1993) . Unless otherwise indicated, we used 9 the pan-neuronal elav-Gal4 driver C155 (Lin and Goodman, 1994) to express these proteins exclusively 10 in otherwise WT neurons (w 1118 ). 11
To evaluate whether WT hCSPα is at least partially functional in fly neurons, we first determined 12 whether neuronally expressed hCSPα is properly palmitoylated and targeted to SVs. This analysis was 13 aided by the availability of species-specific antibodies that discriminate between hCSPα and dCSP (Figs. 14 1B-C, 2A; S1C, S2A). Neuronally expressed hCSPα was efficiently trafficked to axon terminals and co-15 localized with endogenous dCSP in the neuropil of the larval ventral nerve cord (VNC; Fig. 1B ) and larval 16 neuromuscular junctions (NMJs; Fig. 1C ). Consistent with the normal trafficking of hCSPα, the majority of 17 neuronally expressed hCSPα was fully palmitoylated ( Fig. 2A) , which was confirmed by treating larval 18 protein extracts with 0.5 M hydroxylamine (Fig. S1A) . 19 Next, we tested whether hCSPα can functionally replace endogenous dCSP and restore the 20 premature lethality of flies lacking dCSP . Flies and mice lacking CSP due to a 21 gene deletion exhibit progressive neurodegeneration, paralysis and premature death (Fernandez-22 Chacon et al., 2004; Zinsmaier et al., 1994) . Pan-neuronal elav-driven expression of normal hCSPα from 23 one transgenic copy significantly restored adult lifespan of homozygous dcsp deletion mutants from ~4- 5 24 days to 15-20 days (LD50 p<0.001; Fig. 1D ). Even though this rescue was only partial, it confirms that 25 hCSPα is functional in flies, which made a CLN4 Drosophila model using human proteins tenable. 26 Notably, neuronal expression of CLN4 mutant hCSPα in a dcsp null background was able to 27 partially rescue the lifespan deficit (p<0.001, LD50), although not nearly to the extent of wild type hCSPα 28 (Fig. 1D ). This indicates that CLN4 mutant hCSPα proteins are at least partially functional. To test whether expression of CLN4 mutant hCSPα in Drosophila neurons recapitulates the 3 pathological features of post-mortem human brains, we analyzed the properties of CLN4 mutant hCSPα 4 by immunoblotting, using protein extracts from larval VNCs. When expressed from a single transgene 5 with an elav-Gal4 driver, lipidated monomeric protein levels of WT hCSPα were about 0.8-1.5 times of 6 endogenous dCSP levels (data not shown). In comparison, levels of lipidated monomeric hCSP-L115 7 and -L116 were significantly reduced to 13% and 40% of WT hCSPα levels, respectively (p<0.01, Fig.  8 2A, D). Levels of lipidated hCSP-L115 monomers were significantly lower than hCSP-L116 (p<0.05, Fig.  9 2D). Levels of non-lipidated monomeric hCSP-L115 and -L116 were comparable to WT hCSPα levels 10 (p>0.2; Fig. 2A, E) . 11
Both CLN4 mutations induced the formation of SDS-resistant, high-molecular weight hCSPα 12 oligomers in Drosophila neurons (p<0.01; Fig. 2A, C) . In contrast, WT hCSPα oligomers were barely 13 detectable ( Fig. 2A, C) . The mutation L115 triggered oligomerization to a significantly larger degree than 14 L116 (p<0.01; Fig. 2C ), which is consistent with the lower levels of hCSP-L115 monomers (Fig. 2D) . 15 Increasing levels of DTT in the buffer reducing disulfide bonds had little to no effect on the levels and 16 size of hCSP-L115 and -L116 oligomers, which varied widely from ~250 kDa to more than 500 kDa (not 17 shown). 18
To determine whether CLN4 mutant hCSPα oligomers are ubiquitinated, we immunoprecipitated 19 hCSPα from larval brain cell lysates and probed western blots with an antibody that specifically detects 20 K29-, K48-, and K63-linked mono-and poly-ubiquitinated proteins but not free ubiquitin monomers 21 (Fujimuro et al., 1994) . hCSPα antibodies immunoprecipitated both hCSPα monomers and oligomers 22 ( Oligomerization of CLN4-mutant hCSPα is dose-dependent. 31 Oligomerization of purified CLN4 mutant hCSPα proteins is dose-dependent in vitro (Zhang and 32 Chandra, 2014) . To test whether this is also the case in vivo, we doubled mRNA levels of WT and CLN4-33 mutant hCSPα by expressing two copies of the respective transgenes with a single elav-Gal4 driver. In 34 comparison to the expression from one transgene, levels of lipidated and non-lipidated monomeric WT 35 hCSPα increased ~2.4-fold and ~3.3-fold, respectively (p<0.01, Fig. 2A, D-E, H-I ). Yet, WT hCSP 36 oligomer levels increased only 1.5-fold (p<0.01; Fig. 2G ) and remained low such that the 1 oligomer/monomer ratio was not altered (p=0.9; Fig. 2C ). 2
In comparison to single copy gene expression, doubling gene dosage increased levels of 3 lipidated hCSP-L115 monomers only modestly by 1.5-fold (p<0.05) while hCSP-L116 levels were not 4 significantly affected (p=0.3; Fig. 2H ). However, levels of hCSP-L115 and -L116 oligomers increased 4.6-5 and 3.6-fold, respectively (p<0.05; Fig. 2G ). Due to the disproportional increase of CLN4 mutant 6 monomers and oligomers, the oligomer/monomer ratio increased from 0.9 to 2.8 for hCSP-L115 and 7 from 0.4 to 1.8 for hCSP-L116 (Fig. 2C) . Hence, oligomerization of hCSP-L115 and -L116 is dose-8 dependent. 9
Doubling mRNA expression disproportionally increased levels of non-lipidated hCSP-L115 and -10 L116 monomers 8.6-and 4.6-fold, respectively (p<0.01, Fig. 2I ). The increase of non-lipidated mutant 11 monomers is unlikely due to a rate limiting effect on mechanisms mediating palmitoylation because 12 levels of non-lipidated WT monomers increased much less than mutant monomers, even though overall 13 levels of lipidated WT monomers were much higher (Fig. 2E) . 14 Doubling gene dosage of hCSP-L115 and -L116 expression increased total overall protein levels 15 3.0 and 3.9-fold, respectively (p<0.01; Fig. S1D ). It also preserved the relative difference in overall 16 protein levels between WT and CLN4 mutants (Fig. 2F ). Since lipidated mutant monomer levels 17 remained unaltered (p>0.1; Fig. 2D ), the increase in overall protein levels of CLN4 mutant hCSPα is 18 essentially due to increased levels of oligomers and non-lipidated monomers (p<0.05; Fig. 2C, E) . 19 Levels of endogenous dCSP monomers were not affected by low or high expression of CLN4 20 mutant hCSPα (Fig. 2J) . Notably, high-molecular weight oligomers of endogenous WT dCSP were not 21 detectable after expression of CLN4 mutant hCSPα (Fig. S1C ), which contrasts a previous study 22 detecting small amounts of overexpressed GFP-tagged WT hCSPα in CLN4 mutant hCSPα oligomers 23 (Greaves et al., 2012) . 24 
25
Oligomerization of neuronally expressed CLN4-mutant hCSPα precedes lethality. 26 Elav-driven neuronal expression of WT or CLN4-mutant hCSPα from a single transgene had no effect on 27 viability during development (Fig. 3A ) and adult lifespan (not shown). However, doubling gene 28 expression levels severely reduced viability of hCSP-L115 and -L116 animals in comparison to WT 29 hCSPα expression (p<0.001; Fig. 3A ). There was no significant difference between L115 and L116 30 mutant animals (p=0.6; Fig. 3A ). The sharp drop in viability induced by 2-copy expression of hCSP-L115 31
and -L116 indicates a tight threshold of neurotoxicity, which might be linked to the more than 3.6-fold 32 increase of CLN4 mutant CSPα oligomers and/or the more than 4.6-fold increase of non-lipidated 33 monomers (Fig. 2G, I ). 34
Expression of CLN4-mutant hCSPα with the pan-neuronal nSyb-Gal4 driver also caused a dose-35 dependent lethality, which was similar to that of the elav-Gal4 driver (data not shown). In comparison to 36 the elav-driven expression, CLN4-mutant adult escapers were more sluggish and hardly moved. They 1 were also unable to properly inflate their wings (Fig. S1B) and died prematurely within a few days. 2
To further examine potential degenerative effects in adults, we exclusively expressed hCSP-L116 3 in the eye by using the eye-specific GMR-Gal4 driver (Hay et al., 1997) . High-level expression of WT 4 hCSPα from a line with multiple transgene insertions (see methods) had essentially no effect at 23°C or 5 28°C (Fig. 3B) . In contrast, expression hCSP-L116 at 23°C severely impaired the size, integrity and 6 pigmentation of the eye (Fig. 3B) . Raising flies at 28°C to increase Gal4 activity and thereby gene 7 expression enhanced the severity of the degenerative phenotype of L116-mutant eyes (Fig. 3B ). This 8 enhancement is consistent with a dose-dependent increase in hCSP-L116 oligomerization (Fig. 2C, G and HRP marking the neuronal plasma membrane. In comparison to WT hCSPα, levels of mutant hCSP-18 L115 and -L116 were significantly reduced at synaptic boutons (p<0.05; Fig. 4A, H) . Expression of CLN4 19 mutant or WT hCSPα had no effect on synaptic levels of endogenous WT dCSP at NMJs (Fig. 4A, I ). 20
Despite the reduced protein levels, mutant hCSPα still partially rescued the lifespan deficit of dcsp 21 deletion mutants (p<0.001, LD50), although not nearly to the extent of WT hCSPα (Fig. 1D) . This 22 indicates that CLN4 mutant hCSPα proteins are at least partially functional. 23 WT hCSPα co-localized with endogenous dCSP uniformly in the periphery of synaptic boutons 24 (Fig. 4A, C) . In contrast, hCSP-L115 and -L116 were enriched in brightly stained clusters that were more 25 distant from the presynaptic membrane (Fig. 4A, C) . In comparison to control, CLN4 mutant hCSPα also 26 accumulated abnormally in axons of segmental nerves (Fig. 4G ) and the larval brain (p<0.01; Fig. 4B, I , 27 S2A). The size of CLN4 mutant hCSPα accumulations in the larval brain was heterogeneous, ranging 28 from ~500 nm in diameter to ~3 μm in neuronal somata. Occasionally, extreme accumulations of mutant 29 hCSPα were also observed at synaptic boutons of larval NMJs (Fig. S2C) . The occurrence of abnormal 30 hCSP-L115 and -L116 accumulations was also dose-dependent (not shown), which 0was most 31 pronounced in axons of segmental nerves (Fig. 4G) . Hence, CLN4 mutations not only reduce synaptic 32 levels of hCSPα but also cause a severe mislocalization. 33 
34
Abnormal accumulations of CLN4 mutant hCSPα contain WT dCSP and ubiquitinated proteins. 35 A fraction of the abnormal accumulations of hCSP-L115 and -L116 contained significant amounts of 1 endogenous WT dCSP in axons (not shown) and somata (Fig. 4E, S2A ). Since WT dCSP was not 2 detected together with high-molecular weight oligomers of CLN4 mutant hCSPα on Western blots, this 3 indicated that CLN4 mutant hCSPα and WT dCSP may co-accumulate on intracellular membranes. 4 Theoretically, CLN4 mutant hCSPα could accumulate on ER, Golgi, or abnormal SVP 5 membranes during secretory trafficking. Alternatively, mutant hCSPα could accumulate on endosomal 6 membranes that are targeted for degradation. To test whether mutant hCSPα accumulations contain 7 ubiquitinated proteins indicative of prelysosomal membranes, we used antibodies that exclusively detect 8 ubiquitinated proteins but not monomeric ubiquitin (Fujimuro et al., 1994) . Indeed, essentially all CLN4 9 mutant hCSPα accumulations were immunopositive for ubiquitinated proteins in somata and synaptic 10 boutons of NMJs (Fig. 4D, F, S2B ). In comparison to larvae expressing WT hCSPα, the amount of 11 hCSPα accumulations containing ubiquitinated proteins was significantly increased in CLN4 mutants 12 (p<0.001; Fig. 4K ). Hence, the abnormal accumulations of CLN4 mutant hCSPα are either enriched in 13 ubiquitinated hCSPα oligomers and/or contain other ubiquitinated proteins that are potentially destined 14 for protein degradation. 15 
16
CLN4 mutations impair protein homeostasis. 17
The co-immunostainings against hCSPα and ubiquitinated proteins also revealed a substantial increase 18 in the levels of ubiquitinated proteins that were not associated with accumulations of CLN4 mutant 19 hCSPα ( Fig. 4D; S2B) . Brains of control (w 1118 ) and larvae expressing WT hCSPα contained a similar 20 amount of ubiquitinated protein foci that were negative for hCSPα (Fig. 4L) , indicating that expression of 21 WT hCSPα exerts little to no effect on protein ubiquitination. In comparison, the amount of ubiquitinated 22 protein foci that were not associated with mutant hCSPα was significantly increased in brains expressing 23 hCSPα-L115 or -L116 (p<0.05; Fig. 4L ). Hence, CLN4 mutant hCSPα may directly or indirectly affect a 24 step of protein homeostasis that that leads to excessive protein ubiquitination of unrelated proteins. 25
26
CLN4 mutations in fly and human CSP have similar effects. 27
To validate the observed phenotypes of CLN4 mutant hCSPα and exclude that they are not an artefact of 28 expressing mutant human proteins in fly neurons, we expressed CLN4 mutant dCSP2 (dCSP2) 29 containing the mutations V117R and I118Δ, which are analogous to the mutations L115R and L116Δ in 30 hCSPα (Fig. 1A) . All fly transgenes were expressed pan-neuronally with an elav-Gal4 driver from the 31 same transgenic insertion site as the human transgenes. Expression levels of monomeric lipidated 32 dCSP2-V117 and -I118 were reduced in comparison to WT (Fig. S3A ). Similar to its human analog L115 33 ( Fig. 2A) , V117 reduced levels of monomeric dCSP more severely (Fig. S3A ). In addition, both V117 and 34 I118 triggered the formation of SDS-resistant, high-molecular weight oligomers (Fig. S3A ), which were 35 absent for WT dCSP2 expression. Expressing dCSP2-V117 and -I118 in dcsp deletion mutants had 36 similar effects (Fig. S3A) . Hence, the pathological features of the dominant CLN4 mutations reducing 1 levels of lipidated CSP monomers and triggering protein oligomerization are conserved between fly and 2 human CSP. 3
To determine the subcellular localization of CLN4 mutant dCSP in fly neurons, we expressed 4 normal and CLN4 mutant proteins from a single transgene in neurons of homozygous dcsp deletion null 5 mutants. Like for mutant hCSPα, levels of dCSP-V117 and -I118 were reduced at synaptic boutons of 6 larval NMJs and the neuropil of the larval VNC ( Fig. S3B-C) . Mutant dCSP was also mislocalized and 7 accumulated abnormally in axons and neuronal somata of the larval brains (Fig. S3B) . 8 9 CLN4 mutant hCSPα accumulates on prelysosomal endosomes. 10
To further define the nature of the co-accumulations of CLN4 mutant hCSPα with ubiquitinated proteins, 11
we tested a number of organelle markers for a potential colocalization. Mutant hCSPα accumulations did 12 not colocalize with the endoplasmic reticulum (ER), cis-, or trans-Golgi complexes ( Since CLN4 mutant hCSPα abnormally accumulates on prelysosomal endosomes, we used electron 6 microscopy to detect potential ultrastructural defects in membrane trafficking. Expression of hCSPα-L115 7
and -L116 induced highly abnormal membrane structures in neuronal somata, the neuropil of the larval 8 VNC, and axons of segmental nerves (Fig. 6 ). The most prominent and frequent abnormal structures 9
were multilamellar "membrane whirls" of various shapes and density that contain highly electron-dense 10 membranes (arrowheads, Fig. 6A -B, C-D, F-G). Like endosomal hCSPα-positive accumulations detected 11 by confocal microscopy, membrane whirls were most frequently observed in the neuropil of the VNC and 12 axons of segmental nerves ( Fig. 6C-D) . To a lesser degree, they were present in the cytoplasm of 13 neuronal somata ( Fig. 6A-B , F-G) and occasionally the nucleoplasm (not shown). Sporadically, whirls 14 were found on opposite sides of plasma membranes of neighboring cells (arrowhead, Fig. 6B ). 15
In addition to electron-dense membrane whirls, a number of secondary (residual) lysosomes ( Fig.  16 6A, E) and abnormal autophagosome-and/or amphisome-like structures were present (grey arrowhead, 17 Finally, a number of neurons that contained abnormal membrane structures also exhibited a 29 severe fragmentation of the nuclear envelope and bloated Golgi cisternae (Fig. 6B) , which together likely 30 indicate a late stage of neuronal dysfunction and neurodegeneration (Nixon, 2006) . GOF mutation could increase a normal activity of the protein (hypermorphic mutation) or introduce a new 23 activity (neomorphic mutation). In theory, either type of mutation could trigger neurotoxicity. 24
To genetically address the genetic nature of CLN4 mutations, we examined to what degree 25 alterations of WT dCSP or hCSPα levels may affect L115 and L116 phenotypes. The rationale behind 26 these genetic experiments is simple: lowering WT levels should enhance dominant-negative phenotypes, 27 reduce hypermorphic phenotypes that are due to an increased normal activity, or have no effect on 28 neomorphic phenotypes that are due a new protein activity (Muller, 1932; Wilkie, 1994) . 29 Reducing endogenous WT dCSP levels by expressing two transgenic copies of CLN4 mutant 30 hCSP in heterozygous dcsp deletion mutants significantly suppressed the lethality induced by CLN4 31 mutations (p<0.05, Fig. 7A ). Conversely, increasing levels of WT hCSPα enhanced lethality (Fig. 7B-C) . 32 While expression of either WT or CLN4 mutant hCSPα from a single transgene had no effect, co-33 expression of WT hCSPα with either one copy of hCSP-L115 or -L116 significantly reduced viability to 34 ~54% and 48%, respectively (p<0.001, Fig. 7B-C) . The lethality induced by co-expression of WT and 35 CLN4 mutant hCSPα was significantly higher than the lethality induced by 2 copy expression of WT 36 hCSPα (p<0.05, Fig. 7B-C) . Hence, the modulating effects of altered WT dCSP or hCSPα levels on 1 L115-and L116-induced lethality essentially exclude the possibility that either mutation acts as dominant-2 negative. Instead, these effects are consistent with the genetic characteristics of a hypermorphic GOF 3 mutation (Muller, 1932; Wilkie, 1994) . 4 Next, we determined whether altered WT CSP levels may also modulate the tendency of CLN4 5 mutant hCSPα to form abnormal high-molecular weight oligomers. Reducing WT dCSP levels by 6 expressing CLN4 mutant hCSPα in hetero-or homozygous dcsp deletion mutants significantly 7 attenuated the levels of SDS-resistant hCSP-L116 and -L115 oligomers (p<0.05; Fig. 7D, F) . Levels of 8 hCSP-L116 and -L115 oligomers were attenuated to a similar degree (p>0.5; Fig. 7F ). Conversely, 9 increasing WT dCSP levels by co-expressing a WT transgene together with a single CLN4 mutant 10 transgene increased the amount of hCSP-L115 and L116 oligomers (p<0.01, Fig. 7D, I ). Coexpression of 11
WT hCSPα also increased levels of hCSP-L116 and L115 oligomers (Fig. S5) . However, only the 12 increase in hCSP-L116 oligomers (p<0.5) was statistically significant (L115, p=0.09; Fig. 7L ). In 13 comparison, high-level overexpression of WT hCSPα from 2 transgenes did not induce significant protein 14 aggregation ( Fig. 2A, C, S5) . 15 In contrast to the modulatory effects of WT CSP on mutant hCSPα oligomer levels, reducing or 16 even abolishing WT dCSP levels had no effect on the levels of lipidated monomeric hCSP-L115 and -17 L116 (p>0.4; Fig. 7G ). Coexpressing WT dCSP with CLN4 mutant hCSPα slightly but significantly 18 increased lipidated mutant hCSPα monomers (p<0.05; Fig. 7J ) to levels that were similar to those of 2 19 copy WT hCSPα expression (Fig. 7M ). This indicates that WT hCSPα may stabilize CLN4 mutant hCSPα 20
monomers. 21
Levels of non-lipidated monomeric CLN4-mutant hCSP were unaffected by reducing the gene 22 dosage of endogenous WT dCSP (p>0.3; Fig. 7H ). However, coexpression of WT dCSPα with CLN4 23 mutant hCSPα increased levels of non-lipidated mutant hCSPα monomers (p<0.01; Fig. 7K ). Similarly, 24 coexpression of WT hCSPα also increased levels of non-lipidated hCSPα monomers (p<0.05; Fig.7N) . 25
This increase was non-additive since it was significantly larger than the increase induced by doubling WT 26 hCSPα expression (p<0.05; Fig. 7N ). Hence, increased levels of WT CSP may outcompete CLN4 mutant 27 hCSPα for palmitoylation or, alternatively, promote its depalmitoylation. 28
Finally, we tested whether altering levels of endogenous dCSP affects the endosomal 29 accumulation of CLN4 mutant hCSPα. Indeed, reducing dCSP levels by one gene copy significantly 30 reduced the endosomal accumulation of both hCSP-L115 and -L116 in larval VNCs (p<0.05; Fig. 7E, O) . 31
Abolishing endogenous dCSP had a similar effect (Fig. 7O) . (Fig. 3) . 12
Individual expression of Syntaxin 1A (Syx1A), neuronal Synaptobrevin (nSyb), or SNAP25 had no 13 effect on the pigmentation and structure of the eye (not shown). However, co-expression of either Syx1A 14 or nSyb with hCSP-L116 severely enhanced the pigmentation defect and significantly reduced the size of 15 L116 mutant eyes (Fig. 8A) . Overexpression or RNAi-mediated knockdown of SNAP25 had no effect (not 16 shown), even though SNAP25 overexpression enhanced degenerative phenotypes of hCSPα knockout 17 mice (Sharma et al., 2012a) . 18
The genetic modifier effects of Syx1A and nSyb overexpression on CLN4 eye phenotypes 19 indicated that CLN4 toxicity may be at least in part due to an altered chaperone activity of the 20 CSP/Hsc70-complex. If so, one would expect that reducing levels of Hsc70 will suppress these 21
phenotypes. This was indeed the case. Reducing endogenous Hsc70 levels by expressing hCSP-L116 22 in heterozygous Hsc70-4 (Hsc4) deletion mutants suppressed both the structural and depigmentation 23 defects of L116 mutant eyes (Fig. 8A) . Co-expression of three different UAS hairpin transgenes knocking 24 down Hsc4 had a similar suppression effect (Fig. 8A and not shown) . However, reducing the gene 25 dosage of Hsc70-3 or Hsc70-5 had no effect (not shown), indicating that the suppression of L116-mutant 26 eye phenotypes by reduced levels of Hsc4 is not a general effect of Hsc70 proteins. 27 To further test that Hsc4 may at least in part contribute to the toxicity of CLN4 mutations, we hCSP-L115 and -L116 monomers (p<0.05; Fig. 8G-H) . Overall protein levels of mutant hCSP-L115 and -1 L116 were reduced (p<0.05; Fig. 8I ). Reducing Hsc4 protein levels also suppressed the amount of CLN4 2 mutant accumulations on endosomes in the larval brain (p<0.05; Fig. 8K-L, S6) . 3
The overall reduction of CLN4 mutant hCSPα could have been due to a general dependence of 4 hCSPα expression on normal Hsc4 levels. However, this is unlikely the case since reducing Hsc4 levels 5 had no effect on the levels of monomeric WT hCSPα (Fig. 8J) , which was consistent with the normal 6 dCSP levels observed in hsc4 deletion mutants (Bronk et al., 2001 ). Hence, these findings suggest that 7
Hsc4 significantly contributes to the pathology induced by CLN4 mutations. Since Hsc4 colocalized with 8 the abnormal accumulations of hCSP-L115 and -L116 (Fig. 8M) , it may interfere with the prelysosomal 9 trafficking and subsequent degradation of CLN4 mutant hCSPα. This suggestion is consistent with the 10 reduced overall mutant hCSPα levels that are induced by reduced Hsc4 levels (Fig. 8I) . Single copy expression of CLN4 mutant hCSPα did not cause detectable degeneration or 31 lethality, even though significant levels of ubiquitinated hCSPα oligomers and abnormal prelysosomal 32 accumulations of hCSPα were present. However, doubling the gene dosage of mutant hCSPα 33 expression reduced the viability of CLN4 mutant flies, which is likely due to neurodegeneration as 34 indicated by fragmentated nuclear envelopes and "bloated" Golgi cisternae of larval neurons (Fig. 6B) . 35 The significant drop in viability indicated a sharp threshold of neurotoxicity, which was correlated with an 36 increase in the levels of hCSPα oligomers and prelysosomal accumulations. Consistent with a neuronal 1 failure, adult escapers showed reduced locomotor activity. A similar dose-dependent effect on toxicity 2 was observed for the eye phenotype induced by GMR-driven expression of CLN4 mutant hCSPα. 3
The dose-dependent build-up of pathological features towards a threshold of toxicity in the fly 4 model is consistent with the late onset of CLN4 in humans. It also conforms with a post-mortem report of 5 a 37-year old CNL4 patient in a clinically early pre-symptomatic stage who showed all of the pathological 6 features of a terminal patient but had no significant signs of neurodegeneration or cognitive impairment 7 (Benitez et al., 2015) . Finally, the build-up of toxicity in the fly model agrees with the assumed general 8 concept of late onset neurodegenerative diseases, which typically show a progressive accumulation of 9 protein aggregates and defects in protein homeostasis over a long period that is met by an age-10 dependent declining capacity of protein homeostasis (Labbadia and Morimoto, 2015) . one expects that ubiquitinated mutant hCSPα oligomers are sorted into the endolysosomal pathway if 6 they remain associated with membranes. This appears to be the case since the majority of abnormal 7 mutant hCSPα accumulations in fly neurons represented prelysosomal endosomes, which were defined 8 by the colocalization of ubiquitinated proteins and the prelysosomal markers LAMP1-GFP and HRS. 9
Finally, the suppression of mutant hCSPα phenotypes by reduced dCSP or Hsc4 levels revealed a 10 strong link between the oligomerization of mutant hCSPα, its re-routing onto prelysosomal membranes 11 and its induced lethality (Figs. 7-8) . Hence, these data suggest that CLN4 mutations may primarily 12 induce oligomerization of membrane-associated hCSPα, which causes ubiquitination and re-routing into 13 lysosomal pathways. 14 The oligomerization and subsequent rerouting of mutant hCSPα is apparently triggered after 15 exiting the Golgi, either during its association with SVPs, or after arriving at axon terminals and 16 associating with SVs. The transition of SVP cargo onto SVs or endosomes is not well understood but in 17 principle SVPs can fuse with SVs, the synaptic plasma membrane, and endosomes (Rizzoli, 2014) . In GFP. The latter may be due to two alternatives: First, hCSPα-positive endosomes may have normal PI3P 36 levels but most of it is bound by PI3P-binding proteins. At least in part, this could be facilitated by HRS 1 (Raiborg et al., 2001b) , which strongly co-labels with hCSPα accumulations. Alternatively, PI3P could be 2 depleted from these endosomal membranes, which then would imply that HRS is abnormally retained. 3
Since only a small number of mutant hCSPα accumulations co-localized with the early endosome marker 4
Rab5 but essentially no accumulations colocalized with the late endosomal or lysosomal markers Rab7 5 and spinster, it is possible that mutant hCSPα may impair the transition from early to late endosomes. Zhang and Chandra, 2014) . However, CLN4 mutant hCSPα had no effect on the 35 synaptic and overall levels of endogenous WT dCSP, which is inconsistent with the idea of sequestering 36 WT CSP. In addition, genetic characterization of the CLN4 alleles revealed a complex dependence of 1 CLN4 phenotypes on WT CSP levels, which had either a positive or no effect. Both exclude the 2 possibility that the alleles L115 and L116 exert dominant-negative effects. 3
Reducing the gene dosage of WT dCSP had no effect on the levels of monomeric palmitoylated 4 mutant hCSPα, but suppressed the lethality, oligomerization and endosomal accumulation of mutant 5 hCSPα. Vice versa, increasing WT dCSP or hCSPα levels enhanced the latter phenotypes. Hence, these 6 modulatory effects of WT CSP on CLN4 phenotypes suggest that both CLN4 alleles act genetically as 
Material and Methods 14
Drosophila Strains and Husbandry 15
All flies were raised at 23°C on standard cornmeal culture media with a 12/12 light-dark cycle unless 16 otherwise specified. Gal4 driver strains (elav-Gal4 (C155), nSyb-Gal4, GMR-Gal4) and UAS strains 17 accessionID:NP_730714) as template (Nie et al., 1999) . The mutations V117R and I118Δ were 1 introduced into dCSP2 to generate CLN4 mutant dCSP. Both V117R and I118Δ are analogous to the 2 human CLN4 mutations L115R and L116Δ, respectively. The synthesized cDNAs contained a NotI site 3 followed by a Kozak sequence at the 5' end and a Kpn1 site after the stop codon at the 3' end and were 4 inserted into pUC57 plasmids. For transgene expression, the cDNAs were then directionally subcloned 5 into a pBID-UASC vector using the NotI and KpnI cleavage sites. 6
Transgenic animals were generated by ϕC31-based integration (Bischof et al., 2007) embryos (Rainbow Transgenic Flies, Camarillo, CA). At least two independent recombinant strains were 10 obtained for each transgene and out-crossed to exchange non-recombinant chromosomes. The 3xP3-11 RFP cassette was removed by loxP-mediated recombination as described (Bischof et al., 2007 
Electron Microscopy 22
Larvae were rapidly dissected in 4% PFA and then fixed overnight in fresh fixative containing: 3% 23 glutaraldehyde, 1.5% formaldehyde, 2 mM CaCl2, 0.1M sodium cacodylate, pH 7.3. Samples were rinsed 24 in 0.1M cacodylate before being fixed with 2% OsO4 for 2 hours. Next, samples were washed with HPLC 25 grade H2O before being dehydrated with ethanol in a stepped series (30%, 50%, 70%, 90%, 95%,100%) 26 followed by 100% acetone. Tissue was infiltrated with Durcupan ACM plastic embedding media (#14040, 27
Electron Microscopy Sciences, Hatfield, PA) through progressive mixtures with acetone (25%, 50%, 28 75%, 100%), hardened at 60°C, trimmed and sectioned with a diamond knife (70 nm). Sections were 29 poststained with 4% uranyl acetate and lead citrate. Images were obtained on a JEOL 1200EX with an 30 AMT XR80M-B camera running AMT software. For publication, figures were compiled and prepared with 31
Photoshop CC (Adobe). Contrast and intensity of images was minimally adjusted. Images were cropped 32 as needed. 33 
34
Data and Statistical Analysis 35
Data from at least 3 independent animals or experimental trials were used for statistical analysis. were normalized to loading control and plotted as n-fold change from 1-copy expression of WT hCSPα 15 (N = 6). J. Levels of monomeric dCSP shown as n-fold change from control (N = 3). Graphs display 16 mean ± SEM. Statistical analysis used one-way ANOVA (C-F, J) or two-tailed unpaired t test (G-I); *, P < 17 0.05; **, P < 0.01; ***, P < 0.001. O. Cumulative area of endosomal hCSPα accumulations in larval brains (N ≥ 3). Graphs display mean ± 13 SEM. Statistical analysis used two-tailed unpaired t test (A, I-L), or one-way ANOVA (F-H, M-O); *, P < 14 0.05; **, P < 0.01; ***, P < 0.001. 15
